Skip to main content

Table 2 Adverse Events Requiring Dose Reduction

From: First-line single-agent panitumumab in frail elderly patients with wild-type RAS unresectable colorectal cancer: a phase II study protocol OGSG 1602

 

Grade

The modification from next cycle

Skin toxicitiesa

3

Hold dose of treatment and One level dose down

Hypomagnesaemia

3

Pulmonary fibrosis

2

Withdrawal from study

Infusion reaction

3

Hold dose of treatment

  1. aacne, dry skin, nail changes, etc.